进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

REC-994是Recursion立项最早的项目之一，一度也是进度最靠前的临床管线，并且在Ⅱ期研究中，展现出病灶缩小、功能改善的积极信号，但在后续的长期扩展研究中，这种疗效未能维持，转换剂量组也没有积极趋势。

Gibson是临床阶段生物技术公司 Recursion (NASDAQ:RXRX) 的联合创始人兼董事会主席。在Recursion,他领导开发了一个将生物数据生成与机器学习相结合的药物发现平台。他带领公司完成了募集资金、战略合作伙伴关系建立以及公开上市。

Recursion Pharmaceuticals(纳斯达克股票代码:RXRX)于2026年2月25日公布了2025年第四季度及全年业绩,展示了其AI驱动药物发现平台的首次临床验证以及显著的财务纪律。该公司公布的业绩好于预期,2025年第四季度每股收益为-$0.21,超出预期的-$0.30,营收为$35.54百万,超出预期45%。该股在盘前交易中飙升11%至$3.92,反映出投资者对公司临床和运营 ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...